BR0209936A - Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk - Google Patents
Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikkInfo
- Publication number
- BR0209936A BR0209936A BR0209936-5A BR0209936A BR0209936A BR 0209936 A BR0209936 A BR 0209936A BR 0209936 A BR0209936 A BR 0209936A BR 0209936 A BR0209936 A BR 0209936A
- Authority
- BR
- Brazil
- Prior art keywords
- alkoxycarbonyl
- alkoxy
- cyanoguanidine
- inhibitor
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- -1 nitro, sulfo, cyano, amino Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29292801P | 2001-05-24 | 2001-05-24 | |
| PCT/DK2002/000351 WO2002094322A2 (en) | 2001-05-24 | 2002-05-24 | Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0209936A true BR0209936A (pt) | 2004-04-06 |
Family
ID=23126850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0209936-5A BR0209936A (pt) | 2001-05-24 | 2002-05-24 | Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk |
Country Status (17)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| PL228742B1 (pl) * | 2002-05-17 | 2018-05-30 | Leo Pharma As | Proleki cyjanoguanidynowe, kompozycja farmaceutyczna zawierająca te proleki oraz związki pośrednie |
| EP1507759A1 (en) * | 2002-05-17 | 2005-02-23 | Leo Pharma A/S | Cyanoguanidine produgs |
| JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| WO2004047673A2 (en) * | 2002-11-21 | 2004-06-10 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| US20050075341A1 (en) * | 2003-07-17 | 2005-04-07 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
| EP1838696B1 (en) * | 2004-12-22 | 2016-03-09 | Leo Pharma A/S | Novel cyanoguanidine compounds |
| TWI380973B (zh) | 2005-06-30 | 2013-01-01 | Smithkline Beecham Corp | 化合物 |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| JP2009502996A (ja) * | 2005-08-04 | 2009-01-29 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ＩＫＫ−β阻害剤との組合せ |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| AU2009239429B2 (en) | 2008-04-21 | 2013-08-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| AU2010210248B2 (en) * | 2009-02-06 | 2012-08-16 | Tianjin Hemay Bio-Tech Co., Ltd. | Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| TW201216963A (en) | 2010-09-03 | 2012-05-01 | Forma Therapeutics Inc | Novel compounds and compositions for the inhibition of NAMPT |
| EP3313819A1 (en) * | 2015-06-23 | 2018-05-02 | Case Western Reserve University | Compositions and methods for treating cancer |
| CA3029281A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219472D0 (en) * | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| CN1155409C (zh) * | 1996-07-15 | 2004-06-30 | 三共株式会社 | 用于预防和治疗动脉硬化的药物组合物 |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711122D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711119D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711124D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
-
2002
- 2002-05-21 US US10/151,094 patent/US20030045515A1/en not_active Abandoned
- 2002-05-24 PL PL02366462A patent/PL366462A1/xx not_active Application Discontinuation
- 2002-05-24 DE DE60226446T patent/DE60226446D1/de not_active Expired - Fee Related
- 2002-05-24 RU RU2003137006/15A patent/RU2291710C2/ru not_active IP Right Cessation
- 2002-05-24 EP EP02745167A patent/EP1411984B1/en not_active Expired - Lifetime
- 2002-05-24 KR KR10-2003-7015363A patent/KR20040007607A/ko not_active Ceased
- 2002-05-24 AT AT02745167T patent/ATE394100T1/de not_active IP Right Cessation
- 2002-05-24 AU AU2002316795A patent/AU2002316795B2/en not_active Ceased
- 2002-05-24 HU HU0400024A patent/HUP0400024A3/hu unknown
- 2002-05-24 IL IL15882102A patent/IL158821A0/xx unknown
- 2002-05-24 BR BR0209936-5A patent/BR0209936A/pt not_active IP Right Cessation
- 2002-05-24 WO PCT/DK2002/000351 patent/WO2002094322A2/en not_active Ceased
- 2002-05-24 JP JP2002591038A patent/JP2005508857A/ja not_active Withdrawn
- 2002-05-24 CN CNA028121880A patent/CN1516600A/zh active Pending
- 2002-05-24 CA CA002449442A patent/CA2449442A1/en not_active Abandoned
- 2002-05-24 MX MXPA03010691A patent/MXPA03010691A/es unknown
- 2002-05-24 CZ CZ20033189A patent/CZ20033189A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094322A2 (en) | 2002-11-28 |
| RU2003137006A (ru) | 2005-04-10 |
| EP1411984B1 (en) | 2008-05-07 |
| HUP0400024A3 (en) | 2007-05-29 |
| PL366462A1 (en) | 2005-02-07 |
| CZ20033189A3 (cs) | 2004-12-15 |
| RU2291710C2 (ru) | 2007-01-20 |
| US20030045515A1 (en) | 2003-03-06 |
| IL158821A0 (en) | 2004-05-12 |
| CN1516600A (zh) | 2004-07-28 |
| JP2005508857A (ja) | 2005-04-07 |
| AU2002316795B2 (en) | 2007-08-02 |
| HUP0400024A2 (hu) | 2004-04-28 |
| CA2449442A1 (en) | 2002-11-28 |
| MXPA03010691A (es) | 2004-07-01 |
| EP1411984A2 (en) | 2004-04-28 |
| ATE394100T1 (de) | 2008-05-15 |
| DE60226446D1 (de) | 2008-06-19 |
| KR20040007607A (ko) | 2004-01-24 |
| WO2002094322A3 (en) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0209936A (pt) | Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk | |
| BRPI0418639A (pt) | inibidores de dipeptidil peptidase | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| BR0208192A (pt) | Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7. | |
| ES2531660T3 (es) | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio | |
| CO5580803A2 (es) | Derivados de piperidin-bencensulfonamida | |
| UY29886A1 (es) | Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones | |
| BR0312957A (pt) | Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento | |
| BR0208907A (pt) | Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto. | |
| ATE302775T1 (de) | Carbolinderivate | |
| BR0316081A (pt) | Derivados de 2-piridona como inibidores de elastase de neutrófilo | |
| BRPI0417571A (pt) | 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase | |
| UY28623A1 (es) | Derivados de pirazol y usos de los mismos | |
| BR0013041A (pt) | Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método | |
| BRPI0113162B8 (pt) | compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0407591A (pt) | inibidores de transcriptase reversa de não-nucleosìdeo | |
| ATE346067T1 (de) | Carbolinderivate | |
| ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| ATE332903T1 (de) | Kondensierte pyridoindolderivate | |
| HN2003000062A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
| DE60219911D1 (de) | Pyrrolidin-2-on derivate als faktor xa inhibitoren | |
| DK1448562T3 (da) | Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer | |
| NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
| CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
| BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A., E 8A. ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |